argenx Sells $1.7 Billion of VYVGART — and Quietly Buys Its Second Act

A 54% growth quarter, a $4 billion expense line, and a dermatomyositis filing that quietly became another trial

ARGX.BR · Earnings Call · 2026-10-22

The quarter that bought permission to spend

Nearly five years into launch, argenx delivered the kind of quarter that makes an argument for itself. Product net sales of $1.7 billion, up 54% year over year and 13% sequentially, split $1.5 billion U.S., $81 million Japan, $158 million rest of world and $11 million to Zai Lab in China. Operating profit of $486 million on a 28% margin — 37% once you strip the Forte transaction costs. “Product net sales were $1.7 billion, representing growth of 54% year-over-year and 13% quarter-over-quarter.” — Karl Gubitz, Chief Financial Officer · 2026-10-22 That is the unremarkable part. The remarkable part is what management did with the permission it bought. Full-year combined R&D and SG&A guidance moved to roughly $4 billion — a 45% step-up from 2025's ~$2.7 billion. In February, CFO Karl Gubitz had told the Street to expect a similar pace to 2025's ~30% growth. “Looking ahead, you can expect the combined R&D and SG&A to grow at a similar rate with most of the growth in R&D.” — Karl Gubitz, Chief Financial Officer · 2026-02-26 Six months later the pace has accelerated by half again. The company is leaning into the P&L at exactly the moment investors would prefer it leaned on margin. The offsets are real, and Gubitz was careful to pre-empt the extrapolation: “please do not assume another 45% increase into 2027... Think of about half of that 45% if you need something for your models now.” — Karl Gubitz, Chief Financial Officer · 2026-10-22 Roughly half the increase is Forte — $150 million of transaction cost already banked in Q3 plus about $50 million of FB102 operating spend for the remainder of the year. The rest is commercial build for rheumatology and the unglamorous CMC work of having ten assets in the clinic. Guidance-by-conversation is a familiar argenx rhythm; the February call also deferred the number to a later date.

Forte, celiac, and the second pillar problem

What is genuinely new in this quarter's language is the M&A vocabulary. The Forte acquisition and its lead asset FB102 dominate the new keyword set, with celiac disease arriving as a Phase III-ready indication months after the deal closed. Karen Massey frames CD122 as a "pipeline in a product" — celiac, vitiligo already in hand, alopecia coming, more to be unveiled at JPMorgan. Celiac trial design drew the sharpest analyst scrutiny of the Q&A, with the gluten challenge duration and placebo retention emerging as the key design tension. Management would not commit to a design. That is the strategic read: VYVGART is a franchise, but a single-molecule franchise invites a ceiling. The $2.1 billion net paid for Forte — leaving $3.7 billion of cash and current financial assets — is argenx buying the next pillar rather than building it.

What management stopped saying

The most interesting material in this call is the material that shrank. Read the language on dermatomyositis. In July, the framing was that IMNM and DM each had independent statistical shots, and that DM merely needed statistical significance. “if we see effect size in Phase III in the end, that's what we have observed in Phase II, you could make the assumption that because it's twice as long and twice as big that, that would increase the chance for a statistics difference.” — Luc Truyen, Chief Medical Officer · 2026-07-23 Today, after an sBLA meeting, DM is a new registrational trial to be designed, with no timeline. Luc Truyen's explanation is technically honest and strategically deflating: “we missed the primary endpoint. And even though the magnitude of the effect size was exactly as we had seen in IMNM and very consistent, it was felt that this was a really great hypothesis generating data, but that it needed confirmatory evidence.” — Luc Truyen, Chief Medical Officer · 2026-10-22 An asset described as a potential blockbuster a quarter ago is now a 2030 problem. Massey's "our goal is to go as fast as possible" is the language of a company that has lost control of a clock. The second disappearance is Sjögren's. The futility analysis triggered a UNITY wind-down, and Massey pre-emptively fenced off read-through to scleroderma and everything else. Third, the ocular MG PDUFA specificity is gone — in July it was "we'll update you when we have a PDUFA date"; today it is simply "our recent filing in ocular MG." Only pediatric MG carries a hard date, February 2027. And the auto-injector, a top-ten keyword two quarters ago, has slid to a second-half 2027 line item. None of this is alarming on its own. Collectively it is a company quietly re-phasing its own innovation cadence — and the analyst community noticed, with Akash Tewari going straight at Vision 2030's 50,000-patient target post-miss.

I always like to talk about Vision 2030, and we're well on track, and I think I have strong conviction that we'll hit Vision 2030, and we have multiple paths to get there.
Karen Massey, Chief Executive Officer · 2026-10-22

The halo is real, and December is binary

On the commercial side there is one genuinely surprising finding, and it is the best evidence in the entire transcript. The seronegative launch produced a spillover into acetylcholine-receptor-positive patients — new prescribers, simpler no-test prescribing, broader use. “we were a bit surprised by the magnitude of that halo effect. We knew there would be some, but this confirms that it really has an impact beyond just the indication itself.” — Sandrine Piret-Gerard, Chief Commercial Officer · 2026-10-22 That halo effect is now the mechanism by which pediatric and ocular labels are expected to compound rather than merely add, and it explains why Q3 was among the strongest patient-growth quarters since launch despite five years of selling. Then December. The EMPASSION readout in MMN is the second molecule's first Phase III and the difference between a second franchise and a footnote. The design is deliberately provocative — head-to-head against IVIg, powered on non-inferiority with a pre-specified superiority test. Sandrine Piret-Gerard is unambiguous about what counts: “non-inferiority versus IVIg in our MMN trial, we see that as a success. And the superiority would be an add-on and upside.” — Sandrine Piret-Gerard, Chief Commercial Officer · 2026-10-22 Against 12,000 MMN patients in key markets and IVIg infusions that consume up to two days at a time, a tolerable monthly alternative is a defensible commercial thesis even without superiority.

The contrast is the point

Look at what the market's own keyword board is chewing on this quarter: Fed rate hikes, deposit beta, retail deposits, IRB models, brokered funding. Bank and rate mechanics. argenx shares effectively no thematic vocabulary with that list — its entire keyword set is idiosyncratic pipeline and reimbursement language, from unmet need to serotype testing. There is no sector wave here to ride, and no read-across to hide behind. Every catalyst in the next twelve months is a company-specific binary. Which is precisely why the raised expense guide and the muffled DM news matter more than the headline beat. A company spending 45% more to manufacture five launches in a single year — two of which now hinge on a December readout and an FDA agreement it does not yet have — has traded optionality for a schedule. argenx has earned the right to make that bet. What it has not done is tell us how much of the story still depends on the one molecule it already sells.